Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$2.59
EPS est.
$2.54
EPS surprise
+1.97%
1-day move
-0.06%
STERIS plc reported an EPS of $2.59, exceeding expectations, but the stock reacted slightly down by 0.06%. The lack of revenue details and management commentary may have contributed to the muted stock performance. Investors may be cautious given the absence of guidance and additional context from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.59 | N/A | +1.97% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
STERIS plc is a leading provider of health care equipment and services, focusing on sterilization and infection prevention solutions. As a key player in the health care sector, STERIS plays a vital role in ensuring patient safety and operational efficiency in hospitals and medical facilities.
Last quarter
In the last quarter (Q4-2026), STERIS reported an EPS of $2.83, slightly missing the estimate of $2.85. The stock reacted negatively, falling by 2.70% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+1.67%
Avg 1-day reaction
-0.41%
Overall, analysts are cautiously optimistic about STERIS's upcoming earnings, given its historical performance of beating EPS estimates 75% of the time.
Bull case
If STERIS can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products, leading to positive investor sentiment.
Bear case
Conversely, if the company misses expectations again, it may raise concerns about its growth prospects and operational challenges, leading to further stock declines.
Key metrics to watch
EPS
Expecting $2.85Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating revenue.
Revenue Growth
Not availableRevenue growth is essential for assessing the company's ability to expand its market share and sustain operations.
The print will turn on these.
Q1
Will STERIS report an EPS of $2.85 or higher?
Exceeding this EPS estimate would reinforce the company's ability to manage costs and drive profitability, which is crucial for investor confidence.
Q2
What are the revenue growth figures for the quarter?
Revenue growth is vital for assessing the company's market position and future prospects, especially in a competitive health care landscape.
Why consensus could be wrong
The Street may be underestimating the potential for STERIS to exceed EPS expectations given its historical performance and recent operational improvements.
Supporting evidence
The company has a 75% EPS beat rate, indicating a strong track record.
Options pricing suggests a significant move, reflecting investor anticipation of positive news.
Recent operational efficiencies could lead to better-than-expected margins.
Key risk
If EPS comes in below $2.80, it could undermine confidence in STERIS's growth trajectory.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it follows a recent miss, and investors are eager to see if STERIS can regain momentum.
Bull confirmed if
An EPS of $2.85 or higher, along with positive revenue growth, would confirm the bull case.
Bear confirmed if
An EPS below $2.80 or negative revenue growth would support the bear case.
What the market is pricing for the move.
Implied Move
±11.87%
Historical Avg
±1.0%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±11.9% while STE has averaged ±1.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
28.7%
Smart-money positioning from the most recent 13F filings.
Institutional
100.75%
of float
Insider
0.31%
of float
Holders
1,218
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
8,820,889 sh · $1.8B
9.05%
-2.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If STERIS beats expectations, history suggests the stock could see a modest increase, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience limited movement as investors digest management's commentary.
Miss
A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 0.85%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
12
5 buys·7 sells
Members
4
House only
Est. Notional
$125,012.00–$450,000.00
disclosed dollar ranges
Most Active Members
6 trades
The lines on the call that would change the story.
Operating Margin
Not availableOperating margin reflects the efficiency of the company in managing its operational costs relative to its revenue.
Vanguard Capital Management LLC
6,406,906 sh · $1.3B
6.57%
0.6%
State Street Corporation
5,072,818 sh · $1.1B
5.20%
1.6%
Vanguard Portfolio Management LLC
5,001,950 sh · $1.0B
5.13%
1.1%
Morgan Stanley
3,950,067 sh · $828.3M
4.05%
-10.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Mixed
4 trades
Net buying
1 trade
Net selling
1 trade
Net selling
Recent Transactions
Traded Sep 15, 2026 · disclosed Sep 25, 2026
$15,001.00–$50,000.00
Traded Aug 25, 2026 · disclosed Sep 9, 2026
$100,001.00–$250,000.00
Traded Jul 31, 2026 · disclosed Aug 3, 2026
$1,001.00–$15,000.00
Traded Jul 29, 2026 · disclosed Aug 3, 2026
$1,001.00–$15,000.00
Traded Jul 27, 2026 · disclosed Aug 3, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.